All In Biotech

Drug Trial Radar · NCT07883590

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

A Phase 1b, Randomized, Placebo-Controlled, Participant and Investigator-Blinded, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Cytochrome P450 Interaction of Orally Administered LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 13 weeks and will include 6 clinic visits.

Conditions

  • Amyotrophic Lateral Sclerosis
  • Cytochrome P-450 Enzyme System

Interventions

  • LY3873862Drug

    Administered orally

  • CYP450 Drug CocktailDrug

    CYP450 Drug Cocktail (caffeine, midazolam, flurbiprofen, dextromethorphan and omeprazole) administered orally.

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients with One or More Treatment Emergent Adverse Events Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline, Day 28

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Sutter Health Research Institute- California Pacific Medical Center, Van Ness Campus

    San Francisco, California

  • University of Colorado Anschutz

    Aurora, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Northwestern University

    Chicago, Illinois

  • Healey and AMG Center for ALS at Mass General Hospital

    Boston, Massachusetts

  • Montreal Neurological Institute and Hospital

    Montreal, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.